Tag Archives: industry

Healthcare ETFs Have More Room To Run

Summary The Healthcare sector could continue to perform this year. Fundamental factors continue to contribute to growth. Biotech is the leading sub-sector in the healthcare industry. The Healthcare sector exchange traded funds have been outpacing the broader markets and could remain healthy as rising profits diminish concerns over frothy valuations. Over the past year, the Health Care Select Sector SPDR ETF (NYSEARCA: XLV ) rose 25.2%, while the SPDR S&P 500 Trust ETF (NYSEARCA: SPY ) gained 17.1%. Year-to-date, XLV is up 2.5% and SPY is 0.6% higher. Specialized drug treatments, an aging population and industry-wide consolidation, among other factors, will continue to help healthcare stocks, reports Eric Platt for Financial Times . “More than any other sector, healthcare is benefiting from strong demographic and secular trends: aging population, expanding insurance coverage, growing middle-class around the world, new product launches,” Dubravko Lakos-Bujas, equity strategist with J.P. Morgan, said in the Financial Times article. Strong earnings results will support the healthcare sector ‘s rising prices. Healthcare companies reported organic growth of all sectors, including 11% revenue growth and 22% earnings growth over the fourth quarter. Looking ahead, S&P Capital IQ projects S&P 500 healthcare earnings per share to rise 8.9% in 2015 year-over-year, compared to a 1.7% gain in the broader blue-chip index. Barclays strategists also point out that the biotech sub-sector has been a significant contributing factor to earnings growth within the healthcare industry. Over the past year, the iShares Nasdaq Biotechnology ETF (NASDAQ: IBB ) rose 27.2% and the Market Vectors Biotech ETF (NYSEARCA: BBH ) increased 21.9%. The biotech sub-sector makes up 20.3% of XLV’s holdings. “Our conviction level is high on the industry given what we believe will be another strong year for biotech innovation and a differentiated earnings growth profile versus the broader markets,” Geoffrey Meacham, an analyst with Barclays, said in the Financial Times article. Moreover, merger and acquisition (M&A) activity will strengthen valuations. As the market anticipates more deals ahead , consolidations have provided a floor on share prices. Fueling further M&A activity, Marshall Gordon, senior healthcare analyst at ClearBridge Investments, argues that large companies still need to acquire more products, especially as large blockbuster drug patents expire, and financing remains inexpensive. Health Care Select Sector SPDR ETF (click to enlarge) Max Chen contributed to this article . Disclosure: The author is long SPY. (More…) The author wrote this article themselves, and it expresses their own opinions. The author is not receiving compensation for it. The author has no business relationship with any company whose stock is mentioned in this article.

Coca Cola, PepsiCo Earnings Stir Up Consumer Staples ETFs

The beverage space closed out 2014 on a sizzling note as two cola and food bellwethers – Coca Cola Co. (NYSE: KO ) and PepsiCo (NYSE: PEP ) – quenched investors’ thirst with better-than-expected earnings for Q4 ’14. In fact, 2014 will remain especially memorable for PepsiCo as the company beat the Zacks Consensus Estimate for both earnings and revenues in all four quarters. On the other hand, Coca Cola managed to beat on both lines in Q4 after posting mixed results in Q3. Let’s delve a little deeper. Impressive PEP Earnings & Dividend Hike On February 11, PepsiCo beat the Zacks Consensus Estimate for both earnings and revenues. Not only this, the food and beverage behemoth announced a 7.3% increase in annual dividend along with an authorization of a new $12 billion share buyback program. Pepsi’s fourth-quarter core earnings per share of $1.12 easily surpassed the Zacks Consensus Estimate of $1.08 by 3.7% and year-ago earnings by 6% helped by higher organic revenues, improved margins and lower taxes. Total sales of $19.95 billion – down 1% year over year – beat the Zacks Consensus Estimate of $19.78 billion. A stronger snacks performance and improved beverage volumes in Europe and Americas were probably the reasons for the beat. However, it was adverse currency translation which weighed on total revenue growth as currency concerns ate away 6% revenue growth. Pepsi now expects core constant currency earnings per share to increase 7% in 2015, in tune with the long-term management goal of high single-digit core constant currency earnings growth. Notably, currency is expected to mar both earnings per share and revenues by 7% in 2015. Thanks to upbeat earnings, the PepsiCo stock was up about 2.5% in the key trading session of February 11. Coca-Cola Too Posts Decent Earnings On February 10, Coca-Cola reported adjusted earnings of $0.44 per share in Q4 which beat the Zacks Consensus Estimate by around 5%. Earnings declined 5% year over year thanks to a stronger dollar, which was up 5% on a constant currency basis, driven by improved organic revenues and cost-cutting efforts. Net revenue slipped 2% year over year to $10.87 billion due to headwinds from currency and structural changes. Excluding these effects, constant currency revenues grew 4% in the quarter. The best part is that revenues beat the Zacks Consensus Estimate of $10.77 billion by 1%. An extra selling day, better sparkling beverage performance, strong price/mix gains and volume growth in North America helped the company to hold gains. Management remains hopeful about its 2015 operations and sees this as a transition year. However, foreign exchange is expected to hurt 2015 revenues by 5% and profit before tax by 7-8%. While an overall beat offered the KO stock about 2.8% gains in the key trading session of February 10, its shares retreated about 0.1% on February 11. ETF Impact The beverage earnings also put in focus several consumer staples ETFs having notable exposure to Coca Cola and PepsiCo. Funds like Consumer Staples Select Sector SPDR ETF (NYSEARCA: XLP ) , Vanguard Consumer Staples ETF (NYSEARCA: VDC ) and iShares Dow Jones U.S. Consumer Goods Sector ETF (NYSEARCA: IYK ) have large allocations in KO and PEP. Below, we have highlighted these funds in detail: XLP in Focus The most popular consumer ETF in the market, XLP follows the S&P Consumer Staples Select Sector Index. The fund invests about $10.2 billion of assets in 41 holdings. Of these firms, the in-focus Coca-Cola takes the second spot, making up roughly 9.21% of the assets while PepsiCo accounts for about 4.63% of XLP taking up the seventh position. The fund charges 15 bps in fees per year from investors. The fund has added about 1.6% (as of February 11, 2015) post KO earnings. XLP currently has a Zacks ETF Rank #3 (Hold) with a ‘Medium’ risk outlook. VDC in Focus This fund manages a $2.61 billion asset base and provides exposure to a basket of 100 consumer stocks by tracking the MSCI U.S. Investable Market Consumer Staples 25/50 Index. The product charges a low fee of 12 bps per year from investors. Again here, Coca-Cola is the second firm with 8.0% allocation and PepsiCo is the third firm holding 6.7%. The product is widely spread across various sectors out of which soft drinks have a 17.1% allocation. VDC added about 1.6% (as of February 11) within the last two days. VDC currently has a Zacks ETF Rank #3 with a ‘Medium’ risk outlook. IYK in Focus This ETF tracks the Dow Jones U.S. Consumer Goods Index, giving investors exposure to the broad consumer staples space. The fund holds about 115 stocks in its basket with AUM of $516 million, while charging a slightly higher fee of 43 bps per year from investors. Coca-Cola and PepsiCo occupy the second and third positions respectively in the basket with 7.87% and 6.91% of assets. The fund was up 1.63% (As of February 11) post the duo’s earnings. The product has a Zacks ETF Rank #3 with a ‘Medium’ risk outlook. Bottom Line Though the beverage giants ended 2014 with an overall beat and started off 2015 on a refreshing note, currency concerns might surface this year. Plus, the industry fundamentals are also not great as it falls in the bottom 29% section of Zacks Industry Ranks. So, investors having high hopes on the duo might bet on these beverage giants through a basket approach as it partly shields the risk of single-stock investing.

The 7 Deadliest Words Of Investing And Why You Are Not Smarter Than The Average Bear

Summary Stay away from these 7 deadly words that we tell ourselves. See how investors can be classified into three types of lemmings. Discover a simple concept of what valuation really is to an investor. I’m a valuation nut. The methods I choose are not perfect because valuation involves art and science. But then again, what is the perfect valuation method? There’s no such thing. And that’s difficult for many people to grasp because we are taught to do things the “right” way, a “certain” way. One of the most difficult things with investing and any form of valuation is that there is no step by step guide. In any other industry there’s a clear process that you can follow from start to finish to accomplish a task Ikea furniture assembly instructions Photography tutorials How to tie a tie Learning to hang glide and so on But investing is like a choose your own adventure book that I loved to read growing up. A choose your own adventure book is one where you come to a section of the book and then get to choose which adventure you want to take. Depending on your choices, the ending is different. When it comes to investing, there is no clear single method of doing things and it can overwhelm, and frankly, freaks out some people. Instead of a straight path from A to B, the waves of decisions and new information you have to take in requires lots of work. And it’s too much for many people. That’s why you always see people asking strangers what their thoughts are on a stock they hold. But the truth is that people can invest successfully. People can value stocks properly. You’re just led to believe you can’t. It’s just that there are a ton of blogs, news and articles that discuss complex ideas, causing people to simply walk by obvious low risk ideas. I call these low hanging fruits. Bloggers, news reporters, financial analysts all want to write about the hard stuff to get recognized. The complex deals. Who wants to write about how a small, well run, industrial niche company in Nashville, with a 70 year long heritage that continues to gain business and generate cash when less than 400 people on the Internet will read it? Instead they could be writing about how Tesla (NASDAQ: TSLA ) is reinventing the auto industry and revolutionizing a new energy era, poring over PHD words and speculating about what the future could bring. It could go viral and look good on their writing stats. But… You’re led to believe that they must know something that you don’t. The 7 Most Deadly Words in Investing This is a video that I refer to now and then when I need to clear my head or when I start second guessing myself. I’ve marked the video to start from 1:57. Watch the next 2 minutes to around the 3:50 mark. Did you catch those 7 deadly words? They must know something that you don’t. If seasoned professionals fall into this trap, how much easier is it for regular investors to tell themselves the same thing? Especially when they read or hear people they regard as more intelligent as themselves disagreeing with their analysis and valuations. If you didn’t or can’t watch the video above, Prof Aswath Damodaran lays out a simple example that I certainly relate to. You value a company. Say you come up with a value of $50 per share. Let’s say the company is Amazon. Stock is trading at $278. One of the great stocks of the last decade. Your rational side is saying, “don’t buy that stock, it’s expensive”. But then you hear a voice at the back of your head. “They must know something that you don’t”. And when you hear that voice, magical things happen to your valuation. Your cash flows increase, your growth rates go up, your discount rates go down, $50 becomes $100, $100 becomes $150, and before you know it, guess what? You’re at $275, $300, justifying your need to buy. 3 Types of Lemmings Damodaran continues on to group investors into 3 groups of lemmings. After all, we are all lemmings to some degree. There is no such thing as a pure contrarian, because that just means you are a contrarian just for the sake of being a contrarian. Lemming #1: The Proud Lemming These are just momentum investors who are proud of following what’s hot. They don’t care what the company is or does. They look for a crowd and buy and sell whatever is being bought or sold. Lemming #2: The Yogi Bear Lemming Yogi Bear’s tagline is “smarter than the average bear” and it refers to the investors who like to think that they are able to pull out of a stock just before it crashes. The problem is that most people claim they are smarter than the average bear, but rarely are they able to jump ship of a momentum train before it crashes. If Isaac Newton, the father of advanced mathematics and mechanics couldn’t handle the charts, market and lemming fever, I have serious doubts about most of us. Isaac Newton Became a Lemming ( Photo Credit: Safal Niveshak ) Lemming #3: The Lemming with a Life Vest Valuation is simply a life vest. A compass. It’s something for you to hang onto when everyone else is doing something else. Buffett knew that dot com stocks were at stupid valuations in 2000 and held onto his life vest when Barron’s basically called him “old”. After more than 30 years of unrivaled investment success, Warren Buffett may be losing his magic touch. … To be blunt, Buffett, who turns 70 in 2000, is viewed by an increasing number of investors as too conservative, even passe. Buffett, Berkshire’s chairman and chief executive, may be the world’s greatest investor, but he hasn’t anticipated or capitalized on the boom in technology stocks in the past few years. Indeed, Buffett has even started taking flak on Internet message boards. One contributor called Berkshire a “middlebrow insurance company studded with a bizarre melange of assets, including candy stores, hamburger stands, jewelry shops, a shoemaker and a third-rate encyclopedia company [the World Book].” – Barrons I just love how Damodaran puts it because it’s exactly how I process it. Valuation slows the process down, gives your rational side a chance to mount an argument. Valuation is Simple. Don’t Complicate It. When you value stocks, you miss out on hundreds of opportunities. Most growth stocks go out the window. Forget about Tesla. Most investors don’t want to hear about valuation because it challenges their desire to hear what they want. But I love valuation and it’s the reason why the OSV Analyzer came to life in the first place. I love it and over 800 members have made great use of it because when facts and numbers over the past 5 years or 10 years are smack in front on your face, it’s difficult to trick yourself. Unless I can find a reason for why I have to increase my valuation from $50 to $300 without solid evidence, it’s easy to recognize I’m fooling myself. I could go into 101 reasons why everyone should use the analysis tool, but the more important thing is to start building a habit of valuing stocks. Investing is a game where you don’t win by making all the right calls. You can be right only 40% of the time. But if your conviction and position sizing is good, you can easily beat anyone out there. When I start chasing complicated stories, structures, deals, industries that I know nothing about, I’ve lost money every time. When I focus on valuation and follow it up with patiently waiting until the stock hits my margin of safety price, I’ve been rewarded more times than I’ve been wrong. You Can Win the Fight As a freebie, I have free valuation spreadsheets you can start with. It’s combined with an easy to digest mini valuation courses over email if you are a new subscriber. Just easy guides on how to value and analyze stocks using several different methods. Charlie Munger said that if he knew where he was going to die, he’d never go there. Well, you’ve just found the 7 deadliest words in investing. They must know something that you don’t. Let’s not go there. Disclosure: The author has no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. (More…) The author wrote this article themselves, and it expresses their own opinions. The author is not receiving compensation for it. The author has no business relationship with any company whose stock is mentioned in this article.